SUNPHARMA

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has announced its schedule for the second quarter earnings release and conference call, to be held on 30 October 2026.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has submitted a confirmation certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the securities received for dematerialisation during the quarter ended 30 September 2026.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has informed the Exchange about Credit Rating. CRISIL Ratings Limited and ICRA Limited have assigned ratings to the proposed Non-Convertible Debenture programme of Sun Pharmaceutical Industries Limited and reaffirmed the ratings assigned to the existing facilities of the Company.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited announced the resignation of Mr. Gautam Doshi as a Non-Executive, Independent Director of the Company, effective October 12, 2026, citing personal reasons.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited's Board of Directors has approved the issuance of non-convertible debentures (NCDs) up to INR 10,000 Crore and the resignation of Mr. Gautam Doshi as a Non-Executive, Independent Director, citing personal reasons.

Sun Pharmaceutical Industries Limited

Sun Pharma establishes endowed professorship at Mount Sinai to advance dermatologic care, with a $2.5 million endowment to fund academic leadership in dermatology.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has published newspaper advertisements containing information about Postal Ballot/E-Voting. The company has received requests for duplicate share certificates and has opened a special window for shareholders to transfer and dematerialize their shares.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is conducting a Postal Ballot/E-voting to seek shareholders' approval for various proposals, including the adoption of the Sun Pharma Employees Stock Option Plan 2026 (ESOP 2026) and enabling approvals for the proposed acquisition of Organon & Co.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has announced that its drug LEQSELVI (deuruxolitinib) will be featured in seven presentations at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, including a featured oral presentation reporting long-term safety results from a European open-label extension study evaluating up to two years of treatment in adults with severe alopecia areata.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has announced the opening of a special window for the transfer of physical shares, which were sold or purchased prior to April 1, 2019, for a period of one year from February 5, 2026, to February 4, 2027.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has submitted its ESG Overview for FY 2025-26, detailing its environmental, social, and governance performance.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has informed the Exchange regarding the completion and result of the Postal Ballot dated 25 August 2026, where the resolution was approved by the shareholders by the requisite majority.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has entered into a licensing agreement with LIB Therapeutics Inc. for the commercialization and manufacturing of lerodalcibep, a PCSK9 inhibitor, in territories outside the United States and China. The agreement grants Sun Pharma exclusive rights to the drug, which has received EU approval and is approved in the US under a different brand name.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has received approval from its shareholders to reclassify certain individuals from the 'Promoter Group' to the 'Public' category, as per Regulation 31A of the SEBI Listing Regulations.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has closed its trading window for dealing in its shares from 01 October 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended 30 September 2026.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has informed the Exchange about Investor Presentation, which includes revenue composition and growth highlights, business operations, R&D & Manufacturing, corporate governance, key financials, company history and key deals, and focus areas.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has signed a settlement agreement with a plaintiff in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania, U.S. for a confidential amount.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has informed the Exchange about the incorporation of a subsidiary company, Sun Pharma Global Treasury Centre IFSC Limited, in the International Financial Services Centre at GIFT City, Gandhinagar, Gujarat, India.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has been assigned international issuer credit ratings by Moody's Ratings and S&P Global Ratings, with ratings of Baa1 (Stable Outlook) and BBB+ (Stable Outlook) respectively. The ratings reflect Sun Pharma's strong global pharmaceutical franchise, leading market position in India, broad geographic and product diversification, growing innovative medicines portfolio, strong profitability, robust free cash flow generation, and a long track record of conservative financial management.